Medtronic's CoreValve shows efficacy in four-year study
30 August 2011 00:00 in Medical Company Product News
Medtronic has published new data from a four-year study that supports the long-term effectiveness of its CoreValve transcatheter aortic valve replacement system.
The manufacturer has overseen the longest follow-up in a published study of any transcatheter aortic valve implantation system to date, with 50 patients averaging 81 years of age from Europe and Canada having been tracked.
It was found that CoreValve was able to maintain its structural integrity and create positive clinical outcomes over the course of the study, offering high cardiac survival rates, alleviation of heart failure symptoms and a stable valve gradient.
Since 2007, the Medtronic CoreValve System has been implanted in more than 40 countries, while it is also being utilised in investigational applications in the US.
Dr Peter den Heijer, interventional cardiologist at Amphia Hospital Breda in the Netherlands, said: "These results reinforce that CoreValve is a sound and stable valve that holds up to real-world use."
This comes after the company was granted CE Mark accreditation for the new 31mm version of CoreValve last week.
Other news stories from 30/08/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency